𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Factors associated with transfusion requirements during treatment for acute myelogenous leukemia

✍ Scribed by G. Favre; M. Fopp; J. Gmür; A. Tichelli; M. F. Fey; A. Tobler; E. Schatzmann; A. Gratwohl

Publisher
Springer
Year
1993
Tongue
English
Weight
795 KB
Volume
67
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Possible association between Budd-Chiari
Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
✍ Mevlüt Kurt; Ali Shorbagi; Kadri Altundag; Tamer Elkiran; Ibrahim Güllü; Emin Ka 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication